Acta Oncologica最新文献

{"title":"Risk factors for rectal bleeding in prostate cancer after radiotherapy with a validation of current rectal dose constraints.","authors":"Ellen Lund Schaldemose, Christine Vestergaard Madsen, Ahmed Hussein Zedan, Martin Berg, Henrik Dahl Nissen, Terje Andersen, Bjarke Mortensen, Lars Ulrik Fokdal","doi":"10.2340/1651-226X.2025.42551","DOIUrl":"10.2340/1651-226X.2025.42551","url":null,"abstract":"<p><strong>Background: </strong>Rectal bleeding is a well-known adverse event following pelvic external beam radiotherapy (EBRT) for prostate cancer. This study investigates risk factors for rectal bleeding and validate our current rectal dose constraints in a real-world setting.</p><p><strong>Material and methods: </strong>This prospective study includes 248 prostate cancer patients who received EBRT between 2017-2022. EBRT consisted of 56 Gy/39 fractions to the prostate, elective lymph nodes, and seminal vesicles with an integrated boost of 78 Gy to the prostate alone (≤T3a) or to the prostate and seminal vesicles (T3b). Rectal dose constraints were V50 Gy ≤50%, V70 Gy ≤20%, and V74 Gy ≤12%. Rectal bleeding was recorded at baseline and regularly duringfollow-up and included staff reported morbidity and patient reported outcome measures. Risk factors were evaluated in multivariate cox regression analysis.</p><p><strong>Results: </strong>Median follow-up was 18 months (range 1-61 months).  Sixteen percent (CI:11%;22%) of patients reported rectal bleeding as \"rarely\", 4%(CI:2%;8%) \"about half the time\", 0% \"usually\", and 2%(CI:0%;4%) \"always\". Five percent reported rectal bleeding as bothersome. It was possible to comply with current rectal dose constraint (V74 Gy ≤12%) in 99.6% of all patients. Body mass index (BMI) (BMI:25-29.9, HR:0.54(CI:0.30;0.98), p=.044 or BMI>29.9, HR:0.40(CI:0.20;0.79), p=0.008)) were predictors for rectal bleeding.</p><p><strong>Interpretation: </strong>Patient-reported rectal bleeding is common after prostate cancer radiotherapy. High BMI was a protective factor against rectal bleeding. No correlation was observed between rectal dose-volume constraints and the occurrence of rectal bleeding, suggesting that a rectal high-dose constraint of V74 Gy ≤12% is an adequate threshold to minimize patient-reported rectal bleeding.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"644-653"},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balancing between A and I.","authors":"Emma Skovgaard Pedersen, Christoffer Johansen, Mette Kielsholm Thomsen","doi":"10.2340/1651-226X.2025.43320","DOIUrl":"10.2340/1651-226X.2025.43320","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"641-643"},"PeriodicalIF":2.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The risk of myelodysplastic syndrome and acute myeloid leukemia by metformin use and type 2 diabetes status - a Danish nation-wide cohort study.","authors":"Emelie C Rotbain, Klaus Rostgaard, Katja Kaastrup, Stine Ulrik Mikkelsen, Henrik Hjalgrim, Kirsten Grønbæk","doi":"10.2340/1651-226X.2025.42422","DOIUrl":"https://doi.org/10.2340/1651-226X.2025.42422","url":null,"abstract":"<p><strong>Background and purpose: </strong>The treatment options for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have increased recently. However, drug resistance persists and patients who are ineligible for curative treatments still have a very poor prognosis. Previous studies support a general anti-neoplastic effect of metformin, and a recent preclinical investigation has shown that metformin may control the expansion of Dnmt3a clonal hematopoiesis, which is known to precede MDS and AML.</p><p><strong>Patients/material and methods: </strong>In this study we investigated the effect of metformin and type 2 diabetes (T2D) on the risk of developing MDS or AML. T2D was defined based on hospital diagnosis codes and glucose-lowering drug prescriptions. The study was performed as a cohort study with follow-up from 1 January 2000 to 31 December 2017 using Danish national, population-based register data.</p><p><strong>Results and interpretation: </strong>In all, 6,031,132 persons contributed to the study of whom 302,403 had T2D, and 295,365 received metformin. Median follow-up time among individuals with T2D was more than 5 years, and among individuals without T2D more than 15 years. Our analyses revealed no association between T2D (hazard ratio [HR] 1.02 [95% confidence intervals (CI) 0.92-1.13]) or metformin use (HR 1.21 [95% CI 0.91-1.60]) and the risk of MDS or AML. However, when outcomes were studied separately, T2D was associated with an increased risk of MDS (HR 1.24 [95% CI 1.08-1.32]) but not with AML. Metformin use was not associated with MDS nor AML. Future studies should determine which patient groups may benefit from metformin to prevent MDS or AML development.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"623-629"},"PeriodicalIF":2.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment patterns in patients with locally advanced and metastatic bladder cancer in Denmark 2015-2023 - an updated analysis.","authors":"Mette Nørgaard, Aurélie Mailhac, Karin Fagerlund, Torsten Strunz-McKendry, Mads Agerbæk, Jørgen Bjerggaard Jensen","doi":"10.2340/1651-226X.2025.43484","DOIUrl":"https://doi.org/10.2340/1651-226X.2025.43484","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"630-632"},"PeriodicalIF":2.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and treatment outcome in p16 negative anal cancer.","authors":"Catherine Burgos, Calin Radu, Sofia Heyman, Nina Cavalli-Björkman, Peter Nygren","doi":"10.2340/1651-226X.2025.42498","DOIUrl":"https://doi.org/10.2340/1651-226X.2025.42498","url":null,"abstract":"<p><strong>Background: </strong>Anal squamous cell carcinoma (ASCC) is linked to human papillomavirus infection with p16 being positive in about 85% of cases. Overall survival (OS) of ASCC is 60%-80%. Prognosis in p16 negative (p16-) ASCC is worse with an OS of 30%-60%. It is important to elucidate differences in p16+ and p16- ASCC characteristics and outcome.</p><p><strong>Methods: </strong>Consecutive ASCC patients (n = 380) treated with curative intent in Uppsala 2017-2022 were reviewed and analyzed retrospectively. A cohort of p16- patients (n = 30) from Gothenburg was included as a validation cohort.</p><p><strong>Results: </strong>Ninety-one per cent (n = 347) were p16+ and 9% (n = 33) p16-. Median follow-up was 33 months (range 4-78). p16- status was associated with higher age (≥65 years; p = 0.03), comorbidity (p = 0.03), male sex (p = 0.001) and perianal localization (p < 0.001). At 3 years progression free survival was 50% and 81% (p <0.0001) and OS 60% and 89% (p < 0.0001) for p16- and p16+ patients, respectively. Male sex, advanced T-stage (T3-4), N+ disease, advance treatment and p16- status were associated with inferior OS (p = 0.01 - p < 0.0001). In the p16- subgroup, advanced T-stage and intensive treatment were negative prognostic factors for OS (p = 0.007 and 0.009, respectively) but no clinical characteristic predicted persistent disease. The p16- validation cohort essentially confirmed the findings from the main cohort.</p><p><strong>Interpretation: </strong>p16- ASCC is a disease subset with specific clinical features and poor prognosis in need of improved treatment.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"633-640"},"PeriodicalIF":2.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study.","authors":"Xiaoyan Ding, Xue Yin, Linlin Zheng, Lin Zhou, Junke Hu, Wei Sun, Lei Sun, Yanjun Shen, Ying Teng, Yawen Xu, Wendong Li, Mei Liu, Jinglong Chen","doi":"10.2340/1651-226X.2025.42652","DOIUrl":"10.2340/1651-226X.2025.42652","url":null,"abstract":"<p><strong>Background and purpose: </strong>Patients with unresectable hepatocellular carcinoma (uHCC) and Child-Pugh grade B face limited treatment options and poor outcomes. This study aims to evaluate whether the effect and safety of combining tyrosine kinase inhibitors (TKIs) with progressive disease (PD)-1 inhibitors in uHCC patients with Child-Pugh B7 (CP7) and B8/9 (CP8/9) differ.</p><p><strong>Methods: </strong>This multicenter retrospective study included 179 uHCC patients with Child-Pugh B (CP7 group: n = 106; CP8/9 group: n = 73), receiving a combination of lenvatinib/sorafenib/other TKIs and PD-1 inhibitors between December 2020 and March 2023. Progression-free survival (PFS) and overall survival (OS) were defined as the primary endpoint. Secondary endpoints included the objective response rate (ORR) and safety.</p><p><strong>Results: </strong>The median PFS and OS for the entire cohort were 7.3 months (95% confidence intervals [CI]: 6.3-8.3) and 16.0 months (95% CI: 12.9-19.1), respectively. No statistically significant differences were observed between CP7 and CP8/9 groups in PFS (7.8 vs. 6.3 months, p = 0.28), OS (17.8 vs. 14.0 months, p = 0.20), ORR (33.0% vs. 27.4%, p = 0.42), or safety profiles. However, the CP8/9 group had significantly higher rates of TKI dose reductions (46.6% vs. 31.1%, p = 0.04) and discontinuations (57.5% vs. 24.5%, p < 0.001). Notably, 30.2% of patients maintained sustained radiographic responses despite advanced liver dysfunction.</p><p><strong>Interpretation: </strong>Combining TKIs with PD-1 inhibitors is an effective and well-tolerated option for HCC patients with Child-Pugh B, including those with CP8/9.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"607-615"},"PeriodicalIF":2.7,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower MeDiC score is associated with non-referral to multidisciplinary team meeting discussion in bladder cancer patients: a nationwide and population-based study.","authors":"Jessica Wihl, Oskar Hagberg, Firas Aljabery, Truls Gårdmark, Abolfazl Hosseini, Staffan Jahnson, Tomas Jerlström, Viveka Ströck, Karin Söderkvist, Anders Ullén, Lars Holmberg, Christel Häggström, Fredrik Liedberg","doi":"10.2340/1651-226X.2025.42756","DOIUrl":"https://doi.org/10.2340/1651-226X.2025.42756","url":null,"abstract":"<p><strong>Background and purpose: </strong>The Measure of Case-Discussion Complexity (MeDiC) tool was created to gauge case complexity at multidisciplinary team meetings (MDTM) for case selection and prioritization. We aimed to assess applicability and association with MeDiC score and non-compliance with national guideline-recommendations for MDTM referral in a bladder cancer setting.</p><p><strong>Material and methods: </strong>A modified MeDiC scoring system was applied in 8955 subjects with localized (T1-T4N0M0) or metastasized disease as per the Bladder Cancer Data Base Sweden (BladderBaSe) 2.0. Association between MeDiC score and not being discussed at MDTM was investigated by multivariable logistic regression, and further explored in relation to calendar time period, healthcare region, age at diagnosis and hospital volume.</p><p><strong>Results and interpretation: </strong>Median total MeDiC score was lower in individuals not being discussed at an MDTM (7.0 Inter Quartile Range [IQR] 6.0-9.0) compared to those who were (8.0 IQR 6.0-10.0). Adjusted odds ratio for not being discussed at an MDTM was 2.1 (95% confidence interval [CI] 1.8-2.4) for a MeDiC score in the lower quartile, as compared to the highest quartile, with higher estimates when performing stratified analyses in later calendar years and in specific healthcare regions. Our data indicate that the MeDiC score is applicable in bladder cancer patients, and we identified an association between lower MeDiC score and not being discussed at an MDTM.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"616-622"},"PeriodicalIF":2.7,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of treatment practices and outcomes in multiple myeloma during 2013-2022: a Finnish real world registry study.","authors":"Anu Partanen, Marika Waltari, Johanna Vikkula, Riikka Mattila, Katja Närhi, Jonna Eeva, Mervi Putkonen","doi":"10.2340/1651-226X.2025.42647","DOIUrl":"https://doi.org/10.2340/1651-226X.2025.42647","url":null,"abstract":"<p><strong>Background and purpose: </strong>Multiple myeloma (MM) is a heterogenous hematologic malignancy with an evolving treatment landscape. This Finnish real-world evidence study clarifies the evolution of treatment practices and outcomes over recent years.</p><p><strong>Methods: </strong>This retrospective analysis included 1,733 patients with MM diagnosed between 2013 and 2022. The cohort was identified and electronic health record data were collected from four hospital data lakes and linked to national registries, covering 54% of Finland's population. Patients were divided by stem cell transplantation (SCT) status into a SCT group (512 patients) and a non-SCT group (1,221 patients), and further by diagnosis period (2013-2017 vs. 2018-2022).</p><p><strong>Results: </strong>The average age of the patients was 71.3 years at diagnosis. Novel therapeutic use markedly increased during the follow-up, especially lenalidomide as part of frontline and maintenance therapy in SCT patients. For SCT patients the 4-year survival rate improved from 81.7% (95% confidence interval [CI]: 76.4-86.0) in 2013-2017 to 93.0% (95% CI: 87.0-96.3) in 2018-2022. For non-SCT-patients, the median overall survival (OS) increased slightly from 41.3 months (95% CI: 38.1-45.6) in the 2013-2017 period to 43.8 months (95% CI: 39.8-55.3) in the 2018-2022 period, although the difference was not statistically significant. High risk cytogenetics and high International Staging System class appeared to persist as factors indicating shorter OS.</p><p><strong>Interpretation: </strong>While advancements of novel drugs have resulted in a notable survival benefit for patients undergoing SCT, the survival of non-SCT-patients has remained comparatively static. New approaches in the treatment of MM for elderly and frail non-SCT patients are warranted.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"598-606"},"PeriodicalIF":2.7,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental illness and non-metastatic colorectal cancer treatment and survival, a nationwide study of almost 70,000 patients.","authors":"Erik Osterman, Elisavet Syriopoulou, Anna Martling, Therese M-L Andersson, Caroline Nordenvall","doi":"10.2340/1651-226X.2025.42710","DOIUrl":"https://doi.org/10.2340/1651-226X.2025.42710","url":null,"abstract":"<p><strong>Background and purpose: </strong>The impact of mental illness on treatment and outcomes for patients with colorectal cancer (CRC) has not been investigated with potential confounders and mediators accounted for.</p><p><strong>Patients and methods: </strong>Colorectal Cancer Database (CRCBaSe), a linked national registry database, was used to analyse stage I-III CRC patients diagnosed in Sweden between 2008 and 2021. The exposure of interest was a history of mental illness. Treatment outcomes were analysed with logistic regressions. Flexible parametric models were fitted for survival analysis. Analyses were adjusted for pre-specified confounders.</p><p><strong>Results: </strong>Patients with a history of severe mental illness presented with more advanced tumours and comorbidities. They were more likely to undergo emergency surgery (OR 1.56, 95% CI 1.32-1.84) and less likely to receive adjuvant treatment (OR 0.65, 95% CI 0.53-0.80) than patients with no history of mental illness. Five-year standardised overall survival (OS) was worse for those with a history of mild and severe mental illness, 64.6% (95%CI 63.9-65.3) and 61.8% (95%CI 59.7-63.8) compared to those without 69.3% (95%CI 68.9-69.7). Although time to recurrence was not significantly impacted, standardised survival after recurrence was worse for patients with a history of severe mental illness, with a 3-year survival after recurrence of 24% compared to 30% in those without a history of mental illness.</p><p><strong>Interpretation: </strong>Although the differences were smaller compared to previous studies, patients with a history of mental illnesses still do worse. The management of CRC patients with psychiatric comorbidities presents complex challenges necessitating personalised solutions.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"585-594"},"PeriodicalIF":2.7,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and the need for implementation of a health-related quality of life measurement strategy for patients with soft tissue sarcoma undergoing preoperative radiotherapy.","authors":"Geraldien Florine Foppele, Lisette M Wiltink, Marta Fiocco, Jules Lansu, Astrid N Scholten, Winan J Van Houdt, Yvonne Schrage, Winette T A Van der Graaf, Rick L M Haas, Olga Husson","doi":"10.2340/1651-226X.2025.43110","DOIUrl":"https://doi.org/10.2340/1651-226X.2025.43110","url":null,"abstract":"<p><strong>Background and purpose: </strong>Soft tissue sarcomas (STS) are a rare and heterogeneous group of tumours. Treatment strategies are based on histological subtype, patient performance status, tumour location, and size. Common treatment modalities include surgery, (neo)adjuvant chemotherapy, and (neo)adjuvant radiotherapy. While disease control and survival remain primary research focuses, health-related quality of life (HRQoL) is equally important. Accurately assessing HRQoL outcomes is particularly difficult due to the heterogeneity of STS, variations in treatment, tumour location and surgical interventions, and the prevalence of these rare cancers.</p><p><strong>Patients and methods: </strong>To address this gap, a sarcoma-specific tool was developed complementing the most used cancer-generic EORTC QLQ-C30 questionnaire, with additional items tailored to the specific challenges of radiotherapy and surgery in sarcoma patients. The final questionnaire consists of the EQ-5D-5L, EORTC QLQ-C30, and additional EORTC Item Library items addressing stiffness, pain in muscles and bones, scar pain, as well as items of the PRO-CTCAE. The selection was made with significant input from patients with STS who underwent radiotherapy previously and with input from clinicians who were present at the multidisciplinary consultation.</p><p><strong>Results and interpretation: </strong>The newly developed HRQoL tool is currently undergoing validation within the SCOPES trial (NTC04425967), evaluating HRQoL outcomes in patients undergoing standard versus hypofractionated radiotherapy. This tool will lead to better understanding the full impact of treatment on sarcoma patients and hopefully, ultimately improve their HRQoL. Moreover, it provides a standardized framework that can be utilized across studies, facilitating the comparison of HRQoL data and enabling more consistent and comprehensive insights into patient outcomes.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"595-597"},"PeriodicalIF":2.7,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}